SMA50 分钟
Spinraza treatment won’t lead to kidney dysfunction, per study
Spinraza treatment does not lead to significant kidney dysfunction in SMA patients with types 1 and 2, a safety and efficacy ...
openheart.bmj20 小时
Phase 1 study of novel anti-platelet agent to overcome pharmacogenomic limitations of ...
Aims Clopidogrel is the most commonly prescribed thienopyridine as part of dual anti-platelet therapy for the treatment of ...